Academic Highlights: Atypical Antipsychotic Agents in the Treatment of Schizophrenia and Other Psychiatric Disorders. Part I: Unique Patient Populations
J Clin Psychiatry 1998;59(5):259-260
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Click to enlarge page
A large proportion of patients with schizophrenia fail to respond adequately to their medications and can be considered as treatment-refractory, Dr. Stephen R. Marder declared. The advent of newer atypical antipsychotics requires an expanded definition of treatment refractoriness and more thoughtful application of treatment alternatives to the traditional dopamine receptor antagonists. In this context, Dr. Marder discussed positive symptoms and broadened the definition of patients who could be considered treatment- refractory.